Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.53 |
| ▸ | HSP90B1 | P14625 | 5/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14991932 | 0.90 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL10256000 | 0.85 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1HSP90B1HDAC8 | |
| SCHEMBL14856273 | 0.85 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL14856138 | 0.84 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL14856595 | 0.84 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL10256936 | 0.83 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1HSP90B1 | |
| SCHEMBL17923354 | 0.82 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1HSP90B1HDAC8 | |
| SCHEMBL17923353 | 0.82 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1HSP90B1HDAC8 | |
| SCHEMBL14856614 | 0.82 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1HSP90B1 | |
| SCHEMBL14856254 | 0.82 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1HSP90B1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321718-B2 | Benzamide derivatives and their use as HSP90 inhibtors | CHROMA THERAPEUTICS LTD. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20130143926-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD. (GB) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143926-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.